OTHER × Breast Neoplasms × Erlotinib Hydrochloride × Clear all Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
ROME
Phase 2 Unknown
400 enrolled
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
Phase 2 Terminated
11 enrolled 12 charts
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Phase 2 Terminated
27 enrolled 7 charts
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Phase 1/2 Completed
27 enrolled 12 charts
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Phase NA Terminated
44 enrolled 3 charts
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Phase 2 Completed
59 enrolled 14 charts
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase 1/2 Completed
11 enrolled 16 charts
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Phase 1 Completed
9 enrolled
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Phase 1 Completed
8 enrolled
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
Phase 2 Unknown
32 enrolled
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
Phase 2 Completed
61 enrolled
Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
14 enrolled
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
Phase 2 Completed
39 enrolled 7 charts
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Phase 2 Withdrawn
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Phase 2 Completed
50 enrolled 9 charts
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
Phase 2 Terminated
48 enrolled 11 charts
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
Phase 2 Terminated
11 enrolled 5 charts